Neurochemical brain imaging investigations of schizophrenia

Biological Psychiatry

Volumn 46, Issue 5, 1999, Pages 600-615

  Soares, Jair C ^a,b   Innis, Robert B ^a,b  

^a YALE UNIVERSITY   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

MRS; Neuroimaging; PET; Receptor imaging; Schizophrenia; SPECT

Indexed keywords

DOPAMINE; N ACETYLASPARTIC ACID;

CONFERENCE PAPER; CORPUS STRIATUM; DIAGNOSTIC IMAGING; HIPPOCAMPUS; HUMAN; IMAGING; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR DENSITY; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TECHNIQUE;

ASPARTIC ACID; BRAIN; CORPUS STRIATUM; DOPAMINE; GLUTAMIC ACID; HOMOVANILLIC ACID; HUMANS; MAGNETIC RESONANCE IMAGING; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA; SCHIZOPHRENIA; SEROTONIN; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032771114     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00015-3     Document Type: Conference Paper

References (161)

1. Abi-Dargham A., Gil R., Krystal J., et al. Increased striatal dopamine transmission in schizophrenia Confirmation in a second cohort . Am J Psychiatry. 155:1998;761-767.
2. Abi-Dargham A., Krystal J., Laruelle M., et al. SPECT imaging of the benzodiazepine receptor in schizophrenics and healthy subjects (abstract). Schizophr Res. 15:1995;75.
3. Abi-Dargham A., Laruelle M., Aghajanian G.K., Charney D., Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiat Clin Neurosc. 9:1997;1-17.
4. Andreasen N., Carson R., Diksic M., et al. Schizophrenia, positron tomography, and dopamine D2 receptors in the human striatum. Schizophr Bull. 14:1988;471-484.
5. Arnold D.L., Matthews P.M., Francis G., Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis Assessment of the load of disease . MRM. 14:1990;154-159.
6. Arora R.C., Meltzer H.Y. Serotonin2 (5HT2) receptor binding in frontal cortex of schizophrenic patients. J Neural Transm. 85:1991;19-29.
7. Bartha R., Williamson P.C., Drost D.J., et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 54:1997;959-965.
8. A receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci. 12:1992;924-929.
9. Bennett J.P., Enna S.J., Bylund D.B., et al. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry. 36:1979;927-934.
10. Bertolino A., Breier A., Callicott J.H., et al. The relationship between prefrontal neuronal integrity and striatal amphetamine-induced dopamine activity in patients with schizophrenia [abstract]. Neuroimage. 7:1998;531.
11. Bertolino A., Callicott J.H., Elman I., et al. Regionally specific neuronal pathology in untreated patients with schizophrenia A proton magnetic resonance spectroscopic imaging study . Biol Psychiatry. 43:1998;641-648.
12. Bertolino A., Kumra S., Callicott J.H., et al. Common pattern of cortical pathology in childhood onset and adult onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am J Psychiatry. 155:1998;1376-1383.
13. Bertolino A., Nawroz S., Mattay V.S., et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopy imaging. Am J Psychiatry. 153:1996;1554-1563.
14. Bertolino A., Saunders R.C., Mattay V.S., Bachevalier J., Frank J.A., Weinberger D.R. Altered development of prefrontal neurons in rhesus monkeys with neonatal mesial temporo-limbic lesions A proton magnetic resonance spectroscopic imaging study . Cerebral Cortex. 7:1997;740-748.
15. Bird E.D., Barnes J., Iversen L.L., Spokes E.G., Mackay A.V.P., Shepherd M. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychosis. Lancet. 2:1977;1157-1159.
16. Bleich A., Brown S.L., Kahn R., van Praag H.M. The role of serotonin in schizophrenia. Schizophr Bulletin. 14:1988;297-315.
17. Breier A., Su T.P., Saunders R., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations evidence from a novel positron emission tomography method . PNAS. 94:1997;2569-2574.
18. Buckley P.F., Moore C., Long H., et al. H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia Clinical, neurodevelopmental, and cognitive correlates . Biol Psychiatry. 36:1994;792-800.
19. Burnett P.W., Eastwood S.L., Harrison P.J. 5HT1A and 5HT2A receptor mRNAs and binding sites densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-455.
20. Burt D.R., Creese I., Snyder S.S. Antischizophrenic drugs Chronic treatment elevates dopamine receptors binding in brain . Science. 196:1977;326-328.
21. Busatto G.F., Pilowsky L.S., Costa D.C., et al. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiatry. 154:1997;56-63.
22. Bylund D.B., Yamamura H.I. Methods for receptor binding. Yamamura H.I., Enna S.J., Kuhar M.J. Methods in Neurotransmitter Receptor Analysis. 1990;1-35 Raven Press, New York.
23. Calabrese G., Deicken R.F., Fein G., Meirin E.L., Schoenfeld F., Weiner M.W. 31-Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia. Biol Psychiatry. 32:1992;26-32.
24. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
25. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 20:1963;140-144.
26. Cheng L.L., Ma M.J., Becerra L., et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. PNAS. 94:1997;6408-6413.
27. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
28. 2 receptors . Psychopharmacology. 74:1981;122-124.
29. Crow T.J. Molecular pathology of schizophrenia More than one disease process? BMJ. 280:1980;66-68.
30. Crow T.J., Johnstone E.C., Longden A.J., Owen F. Dopaminergic mechanisms in schizophrenia The antipsychotic effect and the disease process . Life Sci. 23:1978;563-567.
31. 3H]GBR12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia. J Neural Transm. 77:1989;227-230.
32. Dao-Castellana M.H., Paillere-Martinot M.L., Hantraye P., et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res. 23:1997;167-174.
33. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia A review and reconceptualization . Am J Psychiatry. 148:1991;1474-1486.
34. De Stefano N., Matthews P.M., Arnold D.L. Reversible decreases in N-acetylaspartate after acute brain injury. MRM. 34:1995;721-727.
35. A receptors in schizophrenia. Schizophr Res. 21:1996;133-139.
36. Deicken R.F., Fein G., Weiner M.W. Abnormal frontal lobe phosphorus metabolism in bipolar disorder. Am J Psychiatry. 152:1995;915-918.
37. Deicken R.F., Zhou L., Schuff N., Fein G., Weiner M.W. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol Psychiatry. 43:1998;483-488.
38. Dewey S.L., Logan J., Wolf A.P., et al. Amphetamine induced decreases in (18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET). Synapse. 7:1991;324-327.
39. Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S.J., Grasby P.M. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature. 378:1995;180-182.
40. Durcan M, Rigdon G, Morgan P (1995): The apparent relative selectivity of dopamine antagonists for D2 and D4 receptor clones depends on the radioligand used. Soc Neurosci Abstr Proceedings, p 617.
41. Engelman K., Jéquier E., Udenfriend S., Sjoerdsma A. Metabolism of alpha-methyltyrosine in man Relationship to its potency as an inhibitor of catecholamine biosynthesis . J Clin Invest. 47:1968;568-576.
42. 2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry. 47:1990;213-219.
43. Friston K.J., Holmes A.P., Worsley K.J., Poline J.P., Frith C.E., Frackowiak R.S.J. Statistical parametric maps in functional imaging A general linear approach . Hum Brain Mapping. 2:1995;189-210.
44. Fujimoto T., Nakano T., Takano T., Hokazono Y., Asakura T., Tsuji T. Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging. Acta Psychiatr Scand. 86:1992;455-462.
45. Fujita M, Al-Tikriti MS, Seibyl JP, et al (1997): Imaging of dopamine D2/3 receptors with [I-123]epidepride - kinetic and equilibrium studies (abstract). J Nucl Med p 81.
46. Fukuzako H., Takeuchi K., Hokazono Y., et al. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia Preliminary report . Psychiatry Res. 61:1995;193-200.
47. Giros B., Jaber M., Jones S., Wightman R., Caron M. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
48. 2 dopamine receptors in the temporal lobe in schizophrenia A postmortem study . Arch Gen Psychiatry. 54:1997;649-658.
49. Grace A.A. Phasic versus tonic dopamine release and modulation of dopamine system responsivity A hypothesis for the etiology of schizophrenia . Neurosci. 41:1991;1-24.
50. Grace A.A. Cortical regulation of subcortical systems and its possible relevance to schizophrenia. J Neural Transm. 91:1993;111-134.
51. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia A postmortem study . Biol Psychiatry. 42:1997;529-545.
52. Haberland N., Hetey L. Studies in postmortem dopamine uptake. II Alterations of the synaptosomal catecholamine uptake in postmortem brain regions in schizophrenia. J Neural Transm. 68:1987;303-313.
53. 2-dopamine receptors in the human brain using [I-125]epidepride. Synapse. 23:1996;115-123.
54. Hanada S., Mita T., Nashimo N., Tanaka C. Muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sciences. 40:1987;258-266.
55. Hashimoto T., Kitamura N., Kajimoto Y., et al. Differential changes in serotonin 5HT1A and 5HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology. 112:1993;S35-S39.
56. Hetherington H.P., Pan J.W., Mason G.F., Adams D., Vaughn M.J., Twieg D.B., et al. Quantitative 1H spectroscopy imaging of the human brain at 4.1 T using image segmentation. Magn Reson Med. 36:1996;21-29.
57. Hietala J., Syvalahti E., Vilkman H., et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res. 35:1999;41-50.
58. 2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry. 51:1994;116-123.
59. Hietala J., Syvalahti E., Vuorio K., et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 346:1995;1130-1131.
60. 2 receptor in nonhuman primates. Synapse. 10:1992;177-184.
61. 2 receptors in basal ganglia and cortex of human brain. J Pharmacol Exp Ther. 257:1991;1253-1263.
62. Joyce J.N., Shane A., Lexow N., et al. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 8:1993;315-336.
63. Kahn R.S., Davidson M. Serotonin receptor responsivity in schizophrenia. Int Clin Psychopharmacol. 8:(Suppl 2):1993;47-51.
64. Kapur S., Remington G. Serotonin-dopamine interactions and its relevance to schizophrenia. Am J Psychiatry. 153:1996;466-476.
65. Kegeles LS, Shungu DC, Chan S, et al (1997): MR spectroscopy of glutamate-containing peaks in hippocampus in schizophrenia. Paper presented at: Society for Neuroscience annual meeting; October 25-30, 1997; New Orleans, LA.
66. Kerwin R.W. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry. 164:1994;141-148.
67. Keshavan M.S., Montrose D.M., Pierri J.N., et al. Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia Preliminary studies . Prog Neuropsychopharmacol Biol Psychiat. 21:1997;1285-1295.
68. 2 receptors. Life Sciences. 49:1991;617-628.
69. 2 receptors in the human brain. Eur J Pharmacology. 223:1992;105-107.
70. 2 receptors. Synapse. 15:1993;169-176.
71. 125I]epidepride. Brain Res. 609:1993;237-243.
72. Kim J., Kornhuber H., Schmid B., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett. 20:1980;379-382.
73. 2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol Psychiatry. 36:1994;827-835.
74. Koepp M.J., Gunn R.N., Lawrence A.D., et al. Evidence for striatal dopamine release during a video game. Nature. 393:1998;266-268.
75. 123I]epidepride Characterization of uptake in the human brain . J Neural Transm - General Section. 101:1995;95-103.
76. Krystal J., Karper L., Seibyl J., et al. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans psychotomimetic, perceptual, cognitive, and neuroendocrine responses . Arch Gen Psychiatry. 51:1994;199-214.
77. 123I]epidepride single-photon emission tomography. Eur J Nucl Med. 24:1997;483-487.
78. Laruelle M. Imaging dopamine transmission in schizophrenia - A review and meta-analysis. Quart J Nucl Med. 42:1998;211-221.
79. Laruelle M., Abi-Dargham A., Casanova M.F., et al. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia A postmortem study . Arch Gen Psychiatry. 50:1993;810-818.
80. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia relationship to illness phase . Biol Psychiatry. 46:1999;56-72.
81. Laruelle M., Abi-Dargham A., Vandyck C.H., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. PNAS. 93:1996;9235-9240.
82. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology. 17:1997;162-174.
83. 2 receptor gene. Mol Psychiatry. 3:1998;261-265.
84. Laruelle M., Iyer R., Al-Tikriti M., et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse. 25:1997;1-14.
85. 3H-apomorphine in schizophrenic brains. Nature. 274:1978;897-900.
86. Lewis R., Kapur S., Jones C., et al. 5HT2 receptors in schizophrenia A PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects . Am J Psychiatry. 156:1998;72-78.
87. 2 receptors in the cerebral cortex Distribution and pharmacological characterization with 3H-raclopride . PNAS. 86:1989;6412-6416.
88. 5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther. 281:1997;597-603.
89. 2-dopamine receptors in primate cerebral cortex. PNAS. 91:1994;4353-4356.
90. 4 dopamine receptor mRNAs in the primate cerebral cortex versus neostriatum Effects of chronic treatment with typical and atypical antipsychotic drugs . J Pharmacol Exp Therap. 283:1997;939-946.
91. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 91:1987;415-433.
92. Lindstrom L, Gefvert O, Lundberg T, Hagstrom P, Hagberg G, Hartvig P, et al (1998): Increased dopamine synthesis in prefrontal cortex and striatum in patients with schizophrenia studied with PET. Paper presented at: CINP meeting; July 12-16, 1998; Glasgow, UK.
93. Lipska B.K., Jaskiw G.E., Weinberger D.R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage A potential animal model of schizophrenia . Neuropsychopharmacology. 9:1993;67-75.
94. Maier M., Ron M.A., Barker G.J., Tofts P.S. Proton magnetic resonance spectroscopy An in vivo method of estimating hippocampal neuronal depletion in schizophrenia . Psychol Med. 25:1995;1201-1209.
95. 2 receptors Evidence for identical binding sites . Eur J Pharmacol. 303:1996;123-128.
96. 2 receptors in chronic schizophrenics. Biol Psychiatry. 21:1986;1407-1414.
97. 2 receptors . Life Sciences. 59:1996;669-678.
98. 2 receptor tracer. Nucl Med and Biol. 22:1995;283-296.
99. Nasrallah H.A., Skinner T.E., Schmalbrock P., Robitaille P.M. Proton magnetic resonance spectroscopy of the hippocampal formation in schizophrenia A pilot study . Br J Psychiatry. 165:1994;481-485.
100. Ng G., O'Dowd B., Lee S., et al. Dopamine receptor dimers and receptor blocking peptides. Biochem Biophys Res Commun. 227:1996;200-204.
101. O'Callaghan E., Redmond O., Ennis R., et al. Initial investigation of the left temporo-parietal region in schizophrenia by 31P magnetic resonance spectroscopy. Biol Psychiatry. 29:1991;1149-1152.
102. 1 receptors in schizophrenia revealed by PET. Nature. 385:1997;634-636.
103. Olney J., Farber N. Glutamate receptor dysfunction in schizophrenia. Arch Gen Psychiatry. 52:1995;998-1007.
104. Owen F., Cross A.J., Longden A., Poulter M., Reilly G.J. Increased dopamine-receptor sensitivity in schizophrenia. Lancet. 2:1978;223-226.
105. Pandey G.N., Conley R.R., Pandey S.C., et al. Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. Psychiat Res. 71:1997;137-149.
106. Pearlson G.D., Marsh L. Structural brain imaging in schizophrenia. Biol Psychiatry. 46:1999;627-649.
107. Perry T.L., Buchanan J., Kish S.J., Hansen S. Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet. 1:1979;237-239.
108. Pettegrew J.W., Keshavan M.S., Panchalingam K., et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy . Arch Gen Psychiatry. 48:1991;563-568.
109. Pike V.W., Halldin C., McCarron J.A., et al. [carbonyl-C-11]desmethyl-WAY-1 00635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo. Eur J Nucl Med. 25:1998;338-346.
110. 11C]WAY-100635. Eur J Pharmacol. 301:1996;R5-R7.
111. 2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry. 164:1994;16-26.
112. 1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur J Pharmacology. 114:1985;235-237.
113. Potwarka J.J., Drost D.J., Williamson P.C., et al. A 1H decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biol Psychiatry. 45:1999;687-693.
114. Pycock C.J., Kerwin R.W., Carter C.J. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 286:1980;74-77.
115. Reith J., Benkelfat C., Sherwin A., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. PNAS. 91:1994;11651-11654.
116. Renshaw P.F., Yurgelun-Todd D.A., Tohen M., Gruber S., Cohen B.M. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am J Psychiatry. 152:1995;444-446.
117. Reynolds G.P. Beyond the dopamine hypothesis, the neurochemical pathology of schizophrenia. Br J Psychiatry. 155:1989;305-316.
118. Reynolds G.P., Rossor M.N., Ivesen L.L. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm. 18:(suppl):1983;273-277.
119. Ross S.B. Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J Neurochem. 56:1991;22-29.
120. 3H-(-)-N-n-propylnorapomorphine in mouse brain. Naunyn-Schmied Arch Pharmacol. 340:1989;13-20.
121. Rothman D.L., Petroff O.A.C., Behar K.L., Mattson R.H. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. PNAS. 90:1993;5562-5666.
122. 1 dopamine receptors in prefrontal cortex involvement in working memory . Science. 251:1991;947-950.
123. Sedvall G. The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology. 7:1992;41-54.
124. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1:1987;133-152.
125. Seeman P., Bzowej N., Guan H., et al. Human brain dopamine receptors in children and aging adults. Synapse. 1:1987;399-404.
126. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsycopharmacology. 1:1987;5-15.
127. 2 receptor reveals different densities for dopamine receptor antagonist ligands - implications for human brain positron emission tomography. Eur J Pharmacol-Molec Pharm. 227:1992;139-146.
128. 4 receptors are elevated in schizophrenia. Nature. 365:1993;441-445.
129. 3H]raclopride Implications for positron emission tomography of the human brain . Synapse. 3:1989;96-97.
130. 3H]benzquinoline. Synapse. 25:1997;137-146.
131. Seeman P., Lee T. Antisychotic drugs Direct correlation between clinical potency and presynaptic action on dopamine neurons . Science. 188:1975;1217-1219.
132. 2 receptors in schizophrenia is underestimated by radioactive raclopride. Arch Gen Psychiatry. 47:1990;1170-1172.
133. Sibson N.R., Dhankhar A., Mason G.F., Behar K.L., Rothman D.L., Shulman R.G. In vivo 13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling. PNAS. 94:1997;2699-2704.
134. Simpson M.D.C., Lubman D.I., Slater P., Deakin J.F.W. Autoradiography with [3H]8-OH-DPAT reveals increase in 5HT1A receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry. 39:1996;919-928.
135. Spector S., Sjoerdsma A., Udenfriend S. Blockade of endogenous norepinephrine synthesis by alpha-methyltyrosine, an inhibitor of tyrosine hydroxylase. J Pharmacol Exp Therap. 147:1965;86-95.
136. Spokes E.G.S., Garrett N.J., Rossor M.N., Iversen L.L. Distribution of GABA in post-mortem brain tissue from control, psychotic, and Huntington's chorea subjects. J Neurol Sci. 48:1980;303-313.
137. Squires R.F., Lajtha A., Saederup E., Palkovits M. [3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains Is selective loss of glutamergic neurons associated with major psychoses? Neurochem Res. 18:1993;219-223.
138. Stanley J., Williamson P.C., Drost D.J., et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry. 5:1995;399-406.
139. Stanley J.A., Williamson P.C., Drost D.J., Carr T., Rylett J., Merskey H. The study of schizophrenia via in vivo 31P and 1H MRS (abstract). Schizophr Res. 9:1993;210.
140. Sulzer D., Chen T.-K., Lau Y., Kristensen H., Rayport S., Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neuroscience. 15:1995;4102-4108.
141. Sumiyoshi T., Stockmeier C.A., Overholser J.C., Dilley G.E., Meltzer H.Y. Serotonin 1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708:1996;209-214.
142. 2 and serotonin-5HT2 receptor occupancy. Neuropsychopharmacology. 12:1995;57-64.
143. Taeber K., Zapf R., Rupp W. Pharmacodynamic comparison of the acute effects of nomifensine, amphetamine and placebo in healthy volunteers. Int J Clin Pharmacol Biopharm. 139:1979;991-997.
144. Toft P.B., Leth H., Lou H.C., Pryds O., Henriksen O. Metabolite concentrations in the developing brain estimated with proton MR spectroscopy. J Magn Res Imag. 4:1994;674-680.
145. Toru M., Watanabe S., Shibuya H., et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand. 78:1988;121-137.
146. Trichard C., Paillere-Martinot M.L., Attar-Levy D., Blin J., Feline A., Martinot J.L. No serotonin 5HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res. 31:1998;13-17.
147. Tsai G., Passani L., Slusher B., et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 52:1995;829-836.
148. 2 receptor quantification and superior temporal gyrus Volume determination in 14 chronic schizophrenic subjects . Psychiatry Res. 67:1996;155-158.
149. 2 receptor density estimates in schizophrenia A positron emission tomography study with 11C-N-methylspiperone . Psychiatry Res. 49:1993;219-237.
150. Urenjak J., Williams S.R., Gadian D.G., Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosciences. 13:1993;981-989.
151. 123I]iomazenil SPECT in schizophrenia. Abstract presented at: Society of Nuclear Medicine annual meeting; June 7-11, 1998; Toronto, Canada.
152. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.
153. Whitaker P.M., Crow T.J., Ferrier I.N. Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry. 38:1981;278-280.
154. 1 receptors in prefrontal cortex. Nature. 376:1995;572-575.
155. Wong D., Solling T., Yokoi F., Gjedde A. Quantification of extracellular dopamine release in schizophrenia and cocaine use by means of TREMBLE. Daube-Witherspoon M.E., Herscovitch P. Quantitative Functional Brain Imaging with Positron Emission Tomography. 1998;463-468 Academic Press, San Diego.
156. 2 dopamine receptors in drug-naive schizophrenics. Science. 234:1986;1558-1563.
157. Wong D.F., Yokoi F., Grunder G., et al. The effect of intrasynaptic dopamine release on measuring Bmax and Bmax/KD in schizophrenia by PET (abstract). J Nucl Med. 38:1997;11.
158. 2-like dopamine receptors - theory, validation, and changes during normal aging. J Cereb Blood Flow and Metab. 17:1997;316-330.
159. 2-like receptors in schizophrenia and bipolar illness . J Cereb Blood Flow and Metab. 17:1997;331-342.
160. Yurgelun-Todd D.A., Renshaw P.F., Gruber S.A., Waternaux C., Cohen B.M. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophr Res. 19:1996;55-59.
161. 2 densities and the schizophrenic brain. Schizophr Res. 32:1998;201-206.